Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Hummel

Nurse Practitioner Selinsgrove, PA Nurse Practitioner

NPI 1477153179 CMS profile 8794184

21 Susquehanna Valley Mall Dr Ste D, Selinsgrove, PA 17870

Open in the dashboard

General payments

$9,213

554 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Hummel of Selinsgrove, PA is reported in the CMS Open Payments database as having received $9,213 across 554 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,749 86
2024 General $2,027 111
2023 General $2,213 134
2022 General $1,491 89
2021 General $1,733 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Hummel
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Laura Hummel were reported at $1,749. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Laura Hummel Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,733 $135 $40–$426 $132
2022 $1,491 $152 $48–$470 $149
2023 $2,213 $166 $54–$529 $160
2024 $2,027 $173 $55–$556 $164
2025 $1,749 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,437 99 payments
  2. Lilly USA, LLC $1,124 70 payments
  3. AbbVie, Inc. $996 53 payments
  4. GlaxoSmithKline, LLC. $745 46 payments
  5. AstraZeneca Pharmaceuticals LP $664 25 payments
  6. Amgen Inc. $393 30 payments
  7. Janssen Pharmaceuticals, Inc $384 31 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $352 23 payments
  9. Pfizer Inc. $305 18 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $256 21 payments
  11. Other $2,556 138 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,201 553 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $1,148 76 payments
  2. RYBELSUS $1,078 71 payments
  3. MOUNJARO $689 38 payments
  4. BREZTRI $419 10 payments
  5. QULIPTA $413 18 payments
  6. Otezla $355 26 payments
  7. XARELTO $354 30 payments
  8. XIFAXAN $352 23 payments
  9. TRELEGY ELLIPTA $330 21 payments
  10. Repatha $310 24 payments
  11. Other $7,238 427 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

1,417

Median for Nurse Practitioner: 389

Drug cost

$90,739

Median for Nurse Practitioner: $21,885

Branded share of claims

20.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 29 $26,188
Jardiance Empagliflozin Brand 25 $21,976
Ozempic Semaglutide Brand 17 $18,291
Breo Ellipta Fluticasone/Vilanterol Brand 17 $6,588
Roflumilast Generic 13 $1,847
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 13 $1,531
Levothyroxine Sodium Generic 53 $1,394
Albuterol Sulfate Hfa Albuterol Sulfate Brand 46 $1,140
Atorvastatin Calcium Generic 74 $725
Losartan Potassium Generic 29 $718

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$42,974

Of which drugs: $5,323

Medicare patients

185

Average age 75

Services billed

2,799

99 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Chronic kidney disease 46%
Diabetes 35%
Depression 26%
Heart failure 23%
COPD 21%
Ischemic heart disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,064
Injection, methylprednisolone acetate, 1 mg J1010 Office 20 1,742 $169
Injection, methylprednisolone acetate, 40 mg J1030 Office 11 19 $70

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 41 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
$204 — —
MOUNJARO
$197 — —
REXULTI
$138 — —
QULIPTA
$121 — —
AIRSUPRA
$114 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 41 with Patron

Records

554 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record